Saltar al contenido
Merck

Matrix metalloproteinase inhibitors: a structure-activity study.

Journal of medicinal chemistry (1998-02-11)
D E Levy, F Lapierre, W Liang, W Ye, C W Lange, X Li, D Grobelny, M Casabonne, D Tyrrell, K Holme, A Nadzan, R E Galardy
RESUMEN

Modifications around the dipeptide-mimetic core of a hydroxamic acid based matrix metalloproteinase inhibitor were studied. These variations incorporated a variety of natural, unnatural, and synthetic amino acids in addition to modifications of the P1' and P3' substituents. The results of this study indicate the following structural requirements: (1) Two key hydrogen bonds must be present between the enzyme and potent substrates. (2) Potent inhibitors must possess strong zinc-binding functionalities. (3) The potential importance of the hydrophobic group at position R3 as illustrated by its ability to impart greater relative potency against stromelysin when larger hydrophobic groups are used. (4) Requirements surrounding the nature of the amino acid appear to be more restrictive for stromelysin than for neutrophil collagenase, 72 kDa gelatinase, and 92 kDa gelatinase. These requirements may involve planar fused-ring aryl systems and possibly hydrogen-bonding capabilities.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Poder inhibidor de MMP GM6001, The GM6001 MMP Inhibitor Powder controls the biological activity of MMP. This small molecule/inhibitor is primarily used for Biochemicals applications.